We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · May 19, 2020

Emricasan in Patients With NASH and F1-F3 Fibrosis

Journal of Hepatology


Additional Info

Journal of Hepatology
A Randomized, Placebo-Controlled Trial of Emricasan in Patients With NASH and F1-F3 Fibrosis
J. Hepatol. 2020 May 01;72(5)816-827, SA Harrison, Z Goodman, A Jabbar, R Vemulapalli, ZH Younes, B Freilich, MY Sheikh, JM Schattenberg, Z Kayali, A Zivony, A Sheikh, J Garcia-Samaniego, SK Satapathy, G Therapondos, E Mena, D Schuppan, J Robinson, JL Chan, DT Hagerty, AJ Sanyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading